A modified HIV drug reversed vision loss and paralysis in mice with MS

Mice that could no longer use their legs or see properly regained both functions after treatment with kamuvudine-9, a chemically modified relative of HIV drugs known as K-9. The result, reported in Science Translational Medicine and announced by the National Institutes of Health on September 23, 2026, comes from a mouse model of multiple sclerosis. It has not been tested for MS in a single person.

Jayakrishna Ambati of the University of Virginia led the work, and the National Eye Institute’s director, Michael F. Chiang, called the reversal of some of MS’s most severe complications “a very compelling translational pathway.” The pathway is not yet a treatment: the NIH announcement itself frames the work as preclinical, and it reports no outcome in a human with MS. The sections below separate what the animals showed from what remains to be tested.

Kamuvudine-9 and the inflammasome

K-9 belongs to a family of compounds derived from nucleoside reverse transcriptase inhibitors, the class of drugs used against HIV. According to the NIH release, the modification targets the inflammasome, the protein complex that sets off the innate immune system’s cell-killing alarm in the brain and spinal cord. K-9 shut down two separate routes by which inflammasomes become activated. That matters because the older picture of MS, in which immune cells attack nerve tissue directly, is, per the NIH-linked coverage, being replaced by a view in which an immune-triggered alarm in the nervous system does much of the damage, and a drug that mutes the alarm might protect tissue that existing immune-suppressing therapies leave exposed.

The mice given the drug were fully protected from neurologic deficits, and, unexpectedly, animals that already had motor impairment and vision loss recovered from both. No other treatment group, including mice given standard MS medicines, recovered as substantially. Levels of neurofilament light chain, a blood marker of nerve damage, were also reduced, and the treated animals kept nerve fibers and their myelin coating.

Ambati described the effect in terms of what current drugs cannot do. As quoted by News-Medical, he said most MS therapies are aimed at preventing the next attack, whereas K-9 prevented further deterioration and let animals recover function they had already lost.

Limits of a mouse model

Every claim in the study applies to mice. The NIH release states that animal results do not guarantee that the drug will work in people, and that formal clinical trials are required. A report in Drug Discovery News describes the findings as preliminary and limited to animal models, and notes that the comparison drug in which no reversal occurred was fingolimod, an approved MS medication.

MS itself is a chronic autoimmune condition in which the immune system damages the myelin that insulates nerve fibers in the brain and spinal cord. The National Institute of Neurological Disorders and Stroke lists vision disturbances, including optic nerve inflammation, among its common early symptoms, and says current disease-modifying medicines aim to regulate or suppress the inflammatory reactions of the disease and slow its course. None of them is described as a cure, and the agency’s summary says the disease usually appears between ages 20 and 40, mostly in women, with flare-ups followed by remission. That is the gap a drug that reverses damage would address, and it is the reason a reversal in mice drew an NIH announcement at all.

Insurance records and the route to trials

The study pairs the animal experiments with human data of a different kind. Analysis of insurance claims covering more than three million people, summarized by News-Medical, found that people taking NRTI-class HIV drugs had a 41 percent lower risk of MS and 36 percent lower annual relapse rates. Those are correlations from records, and causation was not established.

K-9 has a head start on safety: it has already been through clinical trials for other conditions, namely diabetic macular edema and thyroid eye disease, according to coverage of the NIH announcement. That record is part of why the team talks about trials in MS as a next step. It does not mean K-9 is approved for MS or available to patients.

According to Drug Discovery News, the researchers plan to use neurofilament light chain as an objective blood marker for early signs of efficacy in MS patients, which would let a small trial detect a nerve-protecting effect before disability scores move. The paper, DOI 10.1126/scitranslmed.aei2870, was funded by grants from four NIH institutes: the National Eye Institute, the National Institute on Aging, the National Institute on Drug Abuse and the National Institute of General Medical Sciences. The vision and paralysis recoveries it documents belong to mice, and the first human data on K-9 in MS would come only from the trials still to be designed.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview